{
    "organizations": [],
    "uuid": "ea63f83f93c3ee6b64dc651527351cbb8dde29c3",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-juniper-pharmaceuticals-licenses-i/brief-juniper-pharmaceuticals-licenses-intravaginal-ring-platform-to-dar-bioscience-idUSFWN1S212W",
    "ord_in_thread": 0,
    "title": "BRIEF-Juniper Pharmaceuticals Licenses Intravaginal Ring (IVR) Platform To Daré Bioscience",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 25 (Reuters) - Juniper Pharmaceuticals Inc:\n* JUNIPER PHARMACEUTICALS LICENSES INTRAVAGINAL RING (IVR) PLATFORM TO DARÉ BIOSCIENCE\n* JUNIPER PHARMACEUTICALS - ELIGIBLE TO RECEIVE UP TO $43.75 MILLION IN MILESTONES FOR EACH IVR CANDIDATE, PLUS ROYALTIES ON FUTURE SALES\n* JUNIPER PHARMACEUTICALS - UNDER AGREEMENT, DARÉ TO BE RESPONSIBLE FOR CONDUCTING ALL RESEARCH, DEVELOPMENT, AND COMMERCIAL ACTIVITIES FOR PROGRAM Source text for Eikon: Further company coverage:\n ",
    "published": "2018-04-25T20:10:00.000+03:00",
    "crawled": "2018-04-26T21:01:53.064+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "juniper",
        "pharmaceutical",
        "inc",
        "juniper",
        "pharmaceutical",
        "license",
        "intravaginal",
        "ring",
        "ivr",
        "platform",
        "daré",
        "bioscience",
        "juniper",
        "pharmaceutical",
        "eligible",
        "receive",
        "million",
        "milestone",
        "ivr",
        "candidate",
        "plus",
        "royalty",
        "future",
        "sale",
        "juniper",
        "pharmaceutical",
        "agreement",
        "daré",
        "responsible",
        "conducting",
        "research",
        "development",
        "commercial",
        "activity",
        "program",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}